title: Omega-3 fatty acids supplementation improves endothelial function and arterial stiffness in hypertensive patients with hypertriglyceridemia and high cardiovascular risk.
abstract: Association between hypertriglyceridemia and cardiovascular (CV) disease is still controversial. The purpose of this study was to compare omega-3 and ciprofibrate effects on the vascular structure and function in low and high CV risk hypertensive patients with hypertriglyceridemia. Twenty-nine adults with triglycerides 150-499 mg/dL were divided into low (<7.5%) and high (≥7.5%) CV risk, randomized to receive omega-3 fatty acids 1800 mg/d or ciprofibrate 100 mg/d for 12 weeks. Treatment was switched after 8-week washout. Clinical evaluation and vascular tests were assessed at baseline and after intervention. Peripheral (131 ± 3 to 125 ± 3 mm Hg, P < .05) and aortic (124 ± 3 to 118 ± 2 mg/dL, P < .05) systolic blood pressure were decreased by ciprofibrate in low-risk patients. In high-risk patients, pulse wave velocity was reduced (10.4 ± 0.4 to 9.4 ± 0.3 m/s, P < .05) and flow-mediated dilation was increased (11.1 ± 1.6 to 13.5 ± 1.2%, P < .05) by omega-3. In conclusion, omega-3 improved arterial stiffness and endothelial function, pointing out the beneficial effect of this therapy on vascular aging, in high-risk patients.
authors.affiliation: Department of Clinical Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: cela.abreu@gmail.com.
authors.forename: Marcela A
authors.initials: MA
authors.lastname: Casanova
authors.affiliation: Department of Applied Nutrition, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Fernanda
authors.initials: F
authors.lastname: Medeiros
authors.affiliation: Department of Clinical Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Michelle
authors.initials: M
authors.lastname: Trindade
authors.affiliation: Department of Clinical Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Célia
authors.initials: C
authors.lastname: Cohen
authors.affiliation: Department of Clinical Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Wille
authors.initials: W
authors.lastname: Oigman
authors.affiliation: Department of Clinical Medicine, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Mario Fritsch
authors.initials: MF
authors.lastname: Neves
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D058607:Fibric Acids / Q000008:administration & dosage*; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D015228:Hypertriglyceridemia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D063177:Pulse Wave Analysis / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome; D059289:Vascular Stiffness / Q000187:drug effects*
chemical_list: D015525:Fatty Acids, Omega-3; D058607:Fibric Acids; D000960:Hypolipidemic Agents; C019304:ciprofibrate
keywords: Ciprofibrate; arterial stiffness; cardiovascular risk; hypertension; hypertriglyceridemia; omega-3 fatty acids